[1]郝冰,李佳,李秀红,等.118例视网膜母细胞瘤临床治疗分析[J].第三军医大学学报,2020,42(09):942-948.
 HAO Bing,LI Jia,LI Xiuhong,et al.Clinical treatment for retinoblastoma: report of 118 cases[J].J Third Mil Med Univ,2020,42(09):942-948.
点击复制

118例视网膜母细胞瘤临床治疗分析(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
42卷
期数:
2020年第09期
页码:
942-948
栏目:
临床医学
出版日期:
2020-05-15

文章信息/Info

Title:
Clinical treatment for retinoblastoma: report of 118 cases
作者:
郝冰李佳李秀红石安杰刘志彬袁洪峰
陆军军医大学(第三军医大学)大坪医院眼科
Author(s):
HAO Bing LI Jia LI Xiuhong SHI Anjie LIU Zhibin YUAN Hongfeng
Department of Ophthalmology, Daping Hospital, Army Medical University (Third Military Medical University), Chongqing, 400042, China
 
关键词:
视网膜母细胞瘤化疗生存率经瞳孔温热疗法眼球摘除
Keywords:
retinoblastoma chemotherapy survival rate transpupillary thermotherapy enucleation
分类号:
R181.32; R739.72
文献标志码:
A
摘要:

目的探讨118例视网膜母细胞瘤(retinoblastoma,RB)临床治疗特点及预后。方法以2008年2月至2018年2月我科收治的118例RB病例为研究对象,按IIRC(A~E期)和眼外期标准对患眼进行分期,主要根据肿瘤的分期,同时结合患儿身体状况及患儿家长意愿采用静脉化疗、经瞳孔温热疗法(transpupillary thermotherapy,TTT)、冷凝疗法、眼球摘除等方式治疗,随访1~10年,回顾性分析患儿的临床疗效及预后。结果118例患儿共154眼,双眼36例,单眼82例,男性70例,女性48例。初诊患儿年龄1~122(25.94±20.88)个月。化疗41例,化疗联合TTT治疗57例,化疗联合冷凝治疗10例,单纯眼摘10例。154眼治疗后保76眼,总保眼率49.35%(76/154),其中采用化疗联合TTT治疗保47眼,占总保眼数61.84%(47/76)。手术摘除78眼,总摘眼率50.65%(78/154),E期手术摘53眼,占E期患眼84.13%(53/63)。118例患儿随访时间(86.66±5.69)个月,死亡22例,总死亡率18.64%(22/118);存活96例,总存活率81.36%(96/118);单眼RB 5年累积生存率为71.40%,双眼RB 5年累积生存率为80.00%。结论静脉化疗联合TTT治疗是RB患儿保眼球的主要治疗方式,眼球摘除仍然是E期的主要治疗方式,E期RB患儿应慎重选择保眼治疗

Abstract:

ObjectiveTo investigate the characteristics of clinical treatment and prognosis of 118 cases of retinoblastoma (RB). MethodsA total of 118 RB children treated in our department from February 2008 to February 2018 were recruited in this study. All of them were evaluated by the International Classification for Intraocular Retinoblastoma (IIRC, A~E stage) and extraocular staging standard. Mainly according to their tumor stage, combined with their physical condition and the wishes of their parents, treatments such as intravenous chemotherapy, transpupillary thermotherapy (TTT), freezing and enucleation were applied. All cases were followed up for 1 to 10 years, and the clinical efficacy and prognosis of the patients were analyzed retrospectively. ResultsThe 118 enrolled children (154 eyes) were 70 males and 48 females, at an average age of 25.94±20.88 months (1~122 months) at first visit, and 36 of them suffered from bilateral RB and 82 from single. Among them, 41 received chemotherapy, 57 chemotherapy combined with TTT, 10 chemotherapy combined with freezing, and 10 enucleation only. After treatment, 76 eyes (76/154) were salvaged, with a total salvage rate of 49.35%, and of them, 47 eyes were treated with chemotherapy combined with TTT, accounting for 61.84% (47/76). Seventy-eight eyes were enucleated, with a total extraction rate of 50.65% (78/154), and among 63 eyes at stage E, 53 were enucleated, accounting for 84.13%. During the mean follow-up time of 86.66±5.69 months, 22 (18.64%) children died, and 96 cases (81.36%) survived. The 5-year cumulative survival rate of single eye was 71.40%, and of bilateral was 80.00%. ConclusionIntravenous chemotherapy combined with TTT is one of the main ways for RB salvage. Enucleation is still the primary treatment for stage E eyes.

参考文献/References:

[1]ABRAMSON D H, SCHEFLER A C. Update on retinoblastoma[J]. Retina (Philadelphia, Pa.), 2004, 24(6): 828-848. DOI:10.1097/00006982-200412000-00002.
[2]KNUDSON A G Jr. Mutation and cancer: statistical study of retinoblastoma[J]. Proc Natl Acad Sci USA, 1971, 68(4): 820-823. DOI:10.1073/pnas.68.4.820.
[3]BROADDUS E, TOPHAM A, SINGH A D. Incidence of retinoblastoma in the USA: 1975-2004[J]. Br J Ophthalmol, 2009, 93(1): 21-23. DOI:10.1136/bjo.2008.138750.
[4]ORTIZ M V,DUNKEL I J.Retinoblastoma[J].J Child Neurol, 2016, 31(2):227-236.
[5]SHIELDS C L, SHELIL A, CATER J, et al. Development of new retinoblastomas after 6 cycles of chemoreduction for retinoblastoma in 162 eyes of 106 consecutive patients[J]. Arch Ophthalmol, 2003, 121(11): 1571-1576. DOI:10.1001/archopht.121.11.1571.
[6]DEMIRCI H, EAGLE R C Jr, SHIELDS C L, et al. Histopathologic findings in eyes with retinoblastoma treated only with chemoreduction[J]. Arch Ophthalmol, 2003, 121(8): 1125-1131. DOI:10.1001/archopht.121.8.1125.
[7]ZHAO J Y, LI S F, SHI J T, et al. Clinical presentation and group classification of newly diagnosed intraocular retinoblastoma in China[J]. Br J Ophthalmol, 2011, 95(10): 1372-1375. DOI:10.1136/bjo.2010.191130.
[8]DIMARAS H, KIMANI K, DIMBA E A, et al. Retinoblastoma[J]. Lancet, 2012, 379(9824): 1436-1446. DOI:10.1016/s0140-6736(11)61137-9.
[9]SEREGARD S, LUNDELL G, SVEDBERG H, et al. Incidence of retinoblastoma from 1958 to 1998 in Northern Europe: advantages of birth cohort analysis[J]. Ophthalmology, 2004, 111(6): 1228-1232. DOI:10.1016/j.ophtha.2003.10.023.
[10]KIVEL T. The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death[J]. Br J Ophthalmol, 2009, 93(9): 1129-1131. DOI:10.1136/bjo.2008.150292.
[11]LEAL-LEAL C. A multicentre report from the Mexican Retinoblastoma Group[J]. Br J Ophthalmol, 2004, 88(8): 1074-1077. DOI:10.1136/bjo.2003.035642.
[12]NASERIPOUR M, NAZARI H, BAKHTIARI P, et al. Retinoblastoma in Iran: outcomes in terms of patients’ survival and globe survival[J]. Br J Ophthalmol, 2009, 93(1): 28-32. DOI:10.1136/bjo.2008.139410.
[13]CHANG C Y, CHIOU T J, HWANG B, et al. Retinoblastoma in Taiwan: survival rate and prognostic factors[J]. Jpn J Ophthalmol, 2006, 50(3): 242-249. DOI:10.1007/s10384-005-0320-y.
[14]SWAMINATHAN R, RAMA R, SHANTA V. Childhood cancers in Chennai, India, 1990-2001: incidence and survival[J]. Int J Cancer, 2008, 122(11): 2607-2611. DOI:10.1002/ijc.23428.
[15]BOWMAN R J, MAFWIRI M, LUTHERT P, et al. Outcome of retinoblastoma in east Africa[J]. Pediatr Blood Cancer, 2008, 50(1): 160-162. DOI:10.1002/pbc.21080.
[16]ROARTY J D, MCLEAN I W, ZIMMERMAN L E. Incidence of second neoplasms in patients with bilateral retinoblastoma[J]. Ophthalmology, 1988, 95(11): 1583-1587. DOI:10.1016/s0161-6420(88)32971-4.
[17]ABRAMSON D H, DUNKEL I J, BRODIE S E, et al. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma[J]. Ophthalmology, 2008, 115(8): 1398-1404.e1. DOI:10.1016/j.ophtha.2007.12.014.
[18]FRIEDMAN D L,HIMELSTEIN B,SHIELDS C L,et al.Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma[J].J Clin Oncol,2000,18(1):12-17.
[19]SHIELDS C L, MASHAYEKHI A, AU A K, et al. The International Classification of Retinoblastoma predicts chemoreduction success[J]. Ophthalmology, 2006, 113(12): 2276-2280. DOI:10.1016/j.ophtha.2006.06.018.
[20]梁建宏, 黎晓新, 尹虹, 等. 视网膜母细胞瘤患者全身化学药物治疗联合眼部治疗的临床疗效观察[J]. 中华眼底病杂志, 2007(5): 332-335.
LIANG J H, LI X X, YIN H, et al. Therapeutic effect of chemotherapy combined with ophthalmic therapy on retinoblastoma[J]. Chin J Ocular Fundus Dis, 2007(5): 332-335.
[21]BRENNAN R C, QADDOUMI I, BILLUPS C A, et al. Comparison of high-risk histopathological features in eyes with primary or secondary enucleation for retinoblastoma[J]. Br J Ophthalmol, 2015, 99(10): 1366-1371. DOI:10.1136/bjophthalmol-2014-306364.
[22]SURYAWANSHI P, RAMADWAR M, DIKSHIT R, et al. A study of pathologic risk factors in postchemoreduced, enucleated specimens of advanced retinoblastomas in a developing country[J]. Arch Pathol Lab Med, 2011, 135(8): 1017-1023. DOI:10.5858/2010-0311-OAR2.
[23]李彬,顼晓琳.评估视网膜母细胞瘤临床组织病理学高危因素的重要性及需关注的问题[J]. 中华眼科杂志,2014(10):725-728.
LI B, XIANG X L. The importance of evaluating histopathologic high risk factors in retinoblastoma and the related issues[J]. Chin J Ophthalmol, 2014(10):725-728.
[24]SHIELDS C L, MASHAYEKHI A, CATER J, et al. Chemoreduction for retinoblastoma. Analysis of tumor control and risks for recurrence in 457 tumors[J]. Am J Ophthalmol, 2004, 138(3): 329-337. DOI:10.1016/j.ajo.2004.04.032.
[25]TURAKA K, SHIELDS C L, MEADOWS A T, et al. Second malignant neoplasms following chemoreduction with carboplatin, etoposide, and vincristine in 245 patients with intraocular retinoblastoma[J]. Pediatr Blood Cancer, 2012, 59(1): 121-125. DOI:10.1002/pbc.23278.
[26]BENZ M S, SCOTT I U, MURRAY T G, et al. Complications of systemic chemotherapy as treatment of retinoblastoma[J]. Arch Ophthalmol, 2000, 118(4): 577-578.
[27]BERRY J L, JUBRAN R, KIM J W, et al. Long-term outcomes of Group D eyes in bilateral retinoblastoma patients treated with chemoreduction and low-dose IMRT salvage[J]. Pediatr Blood Cancer, 2013, 60(4): 688-693. DOI:10.1002/pbc.24303.
[28]FABIAN I D, STACEY A W, JOHNSON K P, et al. Primary intravenous chemotherapy for group D retinoblastoma: a 13-year retrospective analysis[J]. Br J Ophthalmol, 2017, 101(1): 82-88. DOI:10.1136/bjophthalmol-2016-309710.
[29]KNKELE A, JURKLIES C, WIELAND R, et al. Chemoreduction improves eye retention in patients with retinoblastoma: a report from the German Retinoblastoma Reference Centre[J]. Br J Ophthalmol, 2013, 97(10): 1277-1283. DOI:10.1136/bjophthalmol-2013-303452.
[30]胡慧敏,张伟令,王一卓,等.视网膜母细胞瘤远处转移期的临床特点和治疗及预后分析[J].中华眼科杂志,2017,53(2):121-127. DOI:10.3760/cma.j.issn.0412-4081.2017.02.010.
HU H M, ZHANG W L, WANG Y Z, et al. Clinical features, treatment and prognosis of retinoblastoma in distant metastasis stage[J]. Chin J Ophthalmol, 2017, 53(2): 121-127. DOI:10.3760/cma.j.issn.0412-4081.2017.02.010.
[31]钱江,薛康.晚期视网膜母细胞瘤可否保眼治疗[J]. 中华眼科杂志, 2016, 52(10): 728-732.DOI:10.3760/cma.j.issn.0412-4081.2016.10.003.
QIAN J, XUE K. Eyeball salvage treatment or enucleation for advanced retinoblastoma[J]. Chin J Ophthalmol, 2016, 52(10): 728-732. DOI:10.3760/cma.j.issn.0412-4081.2016.10.003.

相似文献/References:

[1]杨超,王珊,李长春,等.卵巢恶性生殖细胞瘤患儿62例治疗结果分析[J].第三军医大学学报,2012,34(18):1877.
 Yang Chao,Wang Shan,Li Changchun,et al.Outcome of children with malignant ovarian germ cell tumor: a report of 62 cases[J].J Third Mil Med Univ,2012,34(09):1877.
[2]杨洁芳,何雄伟.回生口服液对卵巢上皮癌患者化疗毒副反应的影响[J].第三军医大学学报,2015,37(19 ):2000.
[3]陈显春,杨英,宋爽,等.乳腺癌患者发生化疗性静脉炎的原因分析及防治对策[J].第三军医大学学报,2007,29(21):2055.
[4]斯晓燕,张力.西妥昔单抗联合化疗一线治疗非小细胞肺癌20例临床观察[J].第三军医大学学报,2012,34(20):2063.
 Si Xiaoyan,Zhang Li.Outcomes of cetuximab combined with chemotherapy as first line therapy in 20 patients with non-small cell lung cancer[J].J Third Mil Med Univ,2012,34(09):2063.
[5]罗虎,罗丹,宫亮,等.联合CIK细胞与化疗对比单纯化疗治疗中晚期非小细胞肺癌的Meta分析[J].第三军医大学学报,2012,34(20):2119.
[6]徐灵莉,邓本敏,唐玲,等.护理风险管理能有效提高糖尿病合并恶性肿瘤患者的化疗疗效[J].第三军医大学学报,2013,35(04):351.
 Xu Lingli,Deng Benmin,Tang Ling,et al.Risk management of nursing improves chemotherapy efficiency for diabetic patients with malignant tumor[J].J Third Mil Med Univ,2013,35(09):351.
[7]卢先锋,戴楠,杨宇馨,等.血清uPAR的水平与小细胞肺癌化疗疗效及预后的关系[J].第三军医大学学报,2012,34(22):2318.
 Lu Xianfeng,Dai Nan,Yang Yuxin,et al.Serum uPAR and its relationship with chemosensitivity and prognosis in patients with small cell lung cancer[J].J Third Mil Med Univ,2012,34(09):2318.
[8]董华琼,刘发兰,田婕丽,等.回生口服液联合多西紫杉醇同期放化疗治疗60例食管癌临床分析[J].第三军医大学学报,2012,34(24):2473.
[9]闫霞,曹官铭,王导新.吉西他滨联合卡铂治疗老年非小细胞肺癌的临床评价[J].第三军医大学学报,2007,29(19):1913.
 YAN Xia,CAO Guan-min,WANG Dao-xin.Gemcitabine plus carboplatin regimen in treatment of advanced non-small cell lung cancer in aged patients[J].J Third Mil Med Univ,2007,29(09):1913.
[10]李长毅,张明川,梅同华,等.持续小剂量化疗对A549肺癌PTEN基因和凋亡的影响[J].第三军医大学学报,2007,29(18):1760.
 LI Chang-yi,ZHANG Ming-chuan,MEI Tong-hua,et al.Low-dose metronomic chemotherapy upregulates PTEN and induces apoptosis of A549 pulmonary adenocarcinoma in athymic mice[J].J Third Mil Med Univ,2007,29(09):1760.

更新日期/Last Update: 2020-05-06